drugset / Trial / NCT02559856
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
Phase 4
Completed
72 enrolled
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR) · collabCanadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. Half of the patients will receive apixaban and half will receive rivaroxaban. The main objective is to determine the feasibility of patient recruitment and resources required to follow enrolled patients and inform for a larger, multi-centered trial and to assess which one is safer.
Timeline
- Start
- 2016-05
- Primary completion
- 2017-11
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apixaban | Small molecule | 5 mg | Oral |
| Comparator | Rivaroxaban | Other / unclassified | 20 mg | Oral |